whitepaper
MEA to probe ALS phenotypes in neuronal disease models
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
List view / Grid view
Bit Bio
whitepaper
Consistent, functional lower motor neurons from iPSCs
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
article
A Molecular Portrait of ALS and FTD
In the sections that follow, we dive in on the latest research describing the underlying causes of ALS and a closely related condition known as frontotemporal dementia (FTD), two forms of neurodegenerative disease that share striking similarities in their molecular pathologies.
whitepaper
Application note: Developing next-gen in vitro Huntington’s disease assays
The use of high-density MEAs to probe single cell and network activity electrophysiology of a hiPSC-derived Huntington’s disease model
article
Right model, right complexity: using in vitro human disease cell models in drug discovery
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.
article
Targeting tau – chasing a treatment for Alzheimer’s
Alzheimer’s disease remains one of the largest challenges for the global ageing population. In this article, Victoria Rees, Editor of Drug Target Review, reviews some of the latest research, highlighting how progress has been made in understanding tau as well as how to potentially target this protein as a therapeutic strategy against…
whitepaper
Infographic: Differentiating iPSCs – Which approach works best?
Download this infographic to find out why the method of generating human iPSC-derived cells matters.
article
Drug Target Review Neuroscience ebook 2022
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
whitepaper
Product hub: A reproducible and scalable Huntington’s disease human cell model
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
webinar
Improving Huntington’s disease drug discovery with new reproducible disease models
27 May 2022 | By bit.bio
This webinar explores how a new generation of reproducible and scalable human cell models are being utilised for drug discovery in Huntington’s disease.
news
bit.bio raises $103 million in first close of Series B financing
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
article
Transcriptional reprogramming rescues vascular fate of misidentified pluripotent cell‑derived epithelial cells
A team of scientists has found that a type of cell derived from human stem cells and widely used for brain research and drug development may have been leading researchers astray for years. Here, Dr Raphaël Lis from Weill Cornell Medicine explains how forcing the activity of three known endothelial cell transcription…
article
Drug development in stem cell-derived liver organoid models
To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outlines his research into liver organoids derived from stem cells that can be used to test new…
article
Drug Target Review Stem Cells ebook 2021
Included in this ebook are articles on stem cell-derived liver organoids and pluripotent cell-derived endothelial cells.